Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Conditions:   Sarcoma;   Desmoplastic Small Round Cell Tumor (DSRCT)Intervention:   Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylatorSponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.Recruiting - verified April 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials